Breaking News

Nestlé Health Licenses Codexis’ CDX-6114

Novel, oral enzyme for phenylketonuria is Codexis’ first internally developed biotherapeutic candidate

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialization of Codexis’ novel, oral enzyme CDX-6114 for the management of phenylketonuria (PKU), an orphan metabolic disorder. Nestlé Health Science was granted this option under the companies’ Development, Option and Licensing Agreement from October 2017. CDX-6114 is Codexis’ first internally developed biotherapeutic product candidate.   Codexis will receive a $3 million mileston...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters